[go: up one dir, main page]

MX2019007041A - Metodos y composiciones para tratar la enfermedad de parkinson. - Google Patents

Metodos y composiciones para tratar la enfermedad de parkinson.

Info

Publication number
MX2019007041A
MX2019007041A MX2019007041A MX2019007041A MX2019007041A MX 2019007041 A MX2019007041 A MX 2019007041A MX 2019007041 A MX2019007041 A MX 2019007041A MX 2019007041 A MX2019007041 A MX 2019007041A MX 2019007041 A MX2019007041 A MX 2019007041A
Authority
MX
Mexico
Prior art keywords
disease
compositions
methods
treating parkinson
treating
Prior art date
Application number
MX2019007041A
Other languages
English (en)
Inventor
Matthew Carl Lawyer
Carl Henry Lawyer
Original Assignee
Cove Bio Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cove Bio Llc filed Critical Cove Bio Llc
Publication of MX2019007041A publication Critical patent/MX2019007041A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En el presente documento se proporcionan métodos y composiciones para tratar, mitigar o prevenir la enfermedad de Parkinson mediante la administración de un agente antimalassezia.
MX2019007041A 2016-12-13 2017-12-13 Metodos y composiciones para tratar la enfermedad de parkinson. MX2019007041A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662433324P 2016-12-13 2016-12-13
US201762504898P 2017-05-11 2017-05-11
PCT/US2017/066218 WO2018112106A1 (en) 2016-12-13 2017-12-13 Methods and compositions for treating parkinson's disease

Publications (1)

Publication Number Publication Date
MX2019007041A true MX2019007041A (es) 2022-09-09

Family

ID=62559231

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007041A MX2019007041A (es) 2016-12-13 2017-12-13 Metodos y composiciones para tratar la enfermedad de parkinson.

Country Status (7)

Country Link
EP (1) EP3554496A4 (es)
JP (1) JP2020502269A (es)
CN (1) CN110753543A (es)
AU (1) AU2017376458A1 (es)
CA (1) CA3046501A1 (es)
MX (1) MX2019007041A (es)
WO (1) WO2018112106A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020264076A1 (en) * 2019-06-28 2020-12-30 The Procter & Gamble Company Light augmented treatment method
CN113005086B (zh) * 2021-02-01 2022-10-28 中国科学院遗传与发育生物学研究所 埃博霉素D和Apol8在调控神经干细胞定向神经元分化中的应用
KR102895904B1 (ko) * 2022-02-08 2025-12-04 주식회사 케이제이엠바이오 뇌기능 개선용 조성물의 제조방법 및 뇌기능 개선용 식품 및 약학적 조성물
CN115813841B (zh) * 2023-01-10 2023-09-05 广东迪美新材料科技有限公司 去屑止痒组合物及制备方法、应用，洗发水及制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495538B2 (en) * 1999-06-23 2002-12-17 Zinc Therapeutics, Canada Inc. Zinc ionophores as therapeutic agents
WO2008021970A2 (en) * 2006-08-09 2008-02-21 Reid William K Treatment of motor neuron disease, including certain neurological disorders, motor neuropathies and chronic inflammatory diseases
EP1923041A1 (de) * 2006-10-20 2008-05-21 Symrise GmbH & Co. KG Verwendung von C10-C14-Alkandiolen zur Herstellung eines Mittels zur Prophylaxe und/oder Behandlung von Malassezia-induzierter Schuppenbildung, sowie Zubereitungen enthaltend C10-C14-Alkandiole
WO2008124131A1 (en) * 2007-04-05 2008-10-16 The John Hopkins University Antifungal agents as neuroprotectants
US20110111014A1 (en) * 2007-06-26 2011-05-12 Parkinson's Institute Methods and compositions for treatment of neurological disorders
US20090062244A1 (en) * 2007-09-04 2009-03-05 Joseph Schwarz Pharmaceutical composition
EP2729176A1 (en) * 2011-07-05 2014-05-14 Contera Pharma APS The use of serotonin receptor agonists for treatment of movement disorders
EP3220901B1 (en) * 2014-11-20 2020-02-19 VIB vzw Means and methods for treatment of early-onset parkinson's disease

Also Published As

Publication number Publication date
JP2020502269A (ja) 2020-01-23
EP3554496A1 (en) 2019-10-23
AU2017376458A1 (en) 2019-06-27
EP3554496A4 (en) 2020-05-13
CN110753543A (zh) 2020-02-04
WO2018112106A1 (en) 2018-06-21
AU2017376458A2 (en) 2019-08-01
CA3046501A1 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
ZA202405294B (en) Heterocyclic compounds as immunomodulators
ZA202206806B (en) Benzooxazole derivatives as immunomodulators
MX2022005290A (es) Compuestos heterociclicos como inmunomoduladores.
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
JOP20200152A1 (ar) مركبات حلقية كبرى لعلاج مرض
MX2022005780A (es) Moduladores de receptores estrogenicos.
GEP20217211B (en) Substituted carbonucleoside derivatives useful as anticancer agents
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
GB2541571A (en) Pharmaceutical compositions
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
PH12019500196A1 (en) Compounds and compositions and uses thereof
EP4289820A3 (en) Compounds for use in treating alzheimer's disease in apoe4+/+ patients
ZA201807438B (en) Methods of treating ocular conditions
EP4339192A3 (en) Compounds and compositions for the treatment of cancer
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
MX2019007041A (es) Metodos y composiciones para tratar la enfermedad de parkinson.
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
PH12019500198A1 (en) Compounds and compositions and uses thereof
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
PH12020500510A1 (en) Prophylactic and/or therapeutic agent for diseases involving ido expression
AU2017264839A1 (en) 2-Anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers
PH12018502704A1 (en) Treatment of retinal vascular disease using progenitor cells
PH12019502145A1 (en) Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient